Evidence map›Paper›PMID 37920695›Full record

ReviewCancer management and research2023

Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives.

Andrea Ferrari, Pablo Berlanga, Susanne Andrea Gatz, Reineke A Schoot, Max M van Noesel, Shushan Hovsepyan, Stefano Chiaravalli, Luca Bergamaschi, Veronique Minard-Colin, Nadege Corradini and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Andrea FerrariPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-4724-0517
Pablo BerlangaDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
Susanne Andrea GatzCancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Reineke A SchootPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Max M van NoeselPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Shushan HovsepyanPediatric Cancer and Blood Disorders Center of Armenia, Yerevan, Armenia.
Stefano ChiaravalliPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Luca BergamaschiPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Veronique Minard-ColinDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
Nadege CorradiniDepartment of Pediatric Hematology and Oncology-IHOPe, Léon Bérard Center, Lyon, France.
Rita AlaggioPathology Department, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.
Patrizia GaspariniTumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Bernadette BrennanPediatric Oncology, Royal Manchester Children's Hospital, Manchester, UK.
Michela CasanovaPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sandro PasqualiMolecular Pharmacology Unit, Department of Applied Research and Technological Development, Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniel OrbachSIREDO Oncology Center(Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Fondazione IRCCS Istituto Nazionale dei Tumori · ITUniversité Paris-Saclay · FRBambino Gesù Children's Hospital · ITCancer Research UK Clinical Trials Unit · GBInstitut d’Hématologie et d’Oncologie Pédiatrique · FRPrincess Máxima Center · NLRoyal Manchester Children's Hospital · GBUniversité Paris Sciences et Lettres · FRUniversity Medical Center Utrecht · NL

Funding

Cancer Research UK 28028
6 · The paper itself

Abstract

While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients.

Indexed as

childrennew agentsrelapsesecond line therapysurgerysynovial sarcomaTCR-T cell therapy

Identifiers

PMID37920695
PMCPMC10618684
OpenAlexW4387954936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.